Skip to content
TrialScanner

NCT05012943

The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)

Phase 2/Phase 3CompletedARCTCollaborator

Registry record

Lead sponsor
Vinbiocare Biotechnology Joint Stock Company
Conditions
COVID-19 Vaccines
Primary completion
Jan 18, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05012943 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05012943: The ARCT-154 Self-Amplifying... | TrialScanner